Antibodies inside of a cell can change its outside: Can intrabodies provide a new therapeutic paradigm?

2.50
Hdl Handle:
http://hdl.handle.net/10033/620543
Title:
Antibodies inside of a cell can change its outside: Can intrabodies provide a new therapeutic paradigm?
Authors:
Marschall, Andrea L J; Dübel, Stefan
Abstract:
Challenges posed by complex diseases such as cancer, chronic viral infections, neurodegenerative disorders and many others have forced researchers to think beyond classic small molecule drugs, exploring new therapeutic strategies such as therapy with RNAi, CRISPR/Cas9 or antibody therapies as single or as combination therapies with existing drugs. While classic antibody therapies based on parenteral application can only reach extracellular targets, intracellular application of antibodies could provide specific advantages but is so far little recognized in translational research. Intrabodies allow high specificity and targeting of splice variants or post translational modifications. At the same time off target effects can be minimized by thorough biochemical characterization. Knockdown of cellular proteins by intrabodies has been reported for a significant number of disease-relevant targets, including ErbB-2, EGFR, VEGFR-2, Metalloproteinase MMP2 and MMP9, β-amyloid protein, α-synuclein, HIV gp120, HCV core and many others. This review outlines the recent advances in ER intrabody technology and their potential use in therapy.
Affiliation:
BRICS, Braunschweiger Zentrum für Systembiologie, Rebenring 56, 38106 Braunschweig, Germany.
Citation:
Antibodies inside of a cell can change its outside: Can intrabodies provide a new therapeutic paradigm? 2016, 14:304-8 Comput Struct Biotechnol J
Journal:
Computational and structural biotechnology journal
Issue Date:
2016
URI:
http://hdl.handle.net/10033/620543
DOI:
10.1016/j.csbj.2016.07.003
PubMed ID:
27570612
Type:
Article
Language:
en
ISSN:
2001-0370
Appears in Collections:
publications of the research group system immunology ([BRICS]SIMM)

Full metadata record

DC FieldValue Language
dc.contributor.authorMarschall, Andrea L Jen
dc.contributor.authorDübel, Stefanen
dc.date.accessioned2016-10-07T13:15:15Z-
dc.date.available2016-10-07T13:15:15Z-
dc.date.issued2016-
dc.identifier.citationAntibodies inside of a cell can change its outside: Can intrabodies provide a new therapeutic paradigm? 2016, 14:304-8 Comput Struct Biotechnol Jen
dc.identifier.issn2001-0370-
dc.identifier.pmid27570612-
dc.identifier.doi10.1016/j.csbj.2016.07.003-
dc.identifier.urihttp://hdl.handle.net/10033/620543-
dc.description.abstractChallenges posed by complex diseases such as cancer, chronic viral infections, neurodegenerative disorders and many others have forced researchers to think beyond classic small molecule drugs, exploring new therapeutic strategies such as therapy with RNAi, CRISPR/Cas9 or antibody therapies as single or as combination therapies with existing drugs. While classic antibody therapies based on parenteral application can only reach extracellular targets, intracellular application of antibodies could provide specific advantages but is so far little recognized in translational research. Intrabodies allow high specificity and targeting of splice variants or post translational modifications. At the same time off target effects can be minimized by thorough biochemical characterization. Knockdown of cellular proteins by intrabodies has been reported for a significant number of disease-relevant targets, including ErbB-2, EGFR, VEGFR-2, Metalloproteinase MMP2 and MMP9, β-amyloid protein, α-synuclein, HIV gp120, HCV core and many others. This review outlines the recent advances in ER intrabody technology and their potential use in therapy.en
dc.language.isoenen
dc.rights.urihttp://creativecommons.org/licenses/by-nc-sa/4.0/*
dc.titleAntibodies inside of a cell can change its outside: Can intrabodies provide a new therapeutic paradigm?en
dc.typeArticleen
dc.contributor.departmentBRICS, Braunschweiger Zentrum für Systembiologie, Rebenring 56, 38106 Braunschweig, Germany.en
dc.identifier.journalComputational and structural biotechnology journalen
This item is licensed under a Creative Commons License
Creative Commons
All Items in HZI are protected by copyright, with all rights reserved, unless otherwise indicated.